CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
S0227 | SWOG | Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent; Persistent; or Metastatic Carcinoma of the Cervix | Adult CIRB - Late Phase Emphasis | Completed |
S1512 | SWOG | A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) | Adult CIRB - Late Phase Emphasis | Available to Open |
S1614 | SWOG | A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors | Cancer Prevention and Control CIRB | Available to Open |
S0124 | SWOG | Randomized Phase III Trial of Cisplatin (NSC-119875) and Irinotecan (NCSC-616348) Versus Cisplatin and Etoposide (NSC-141540) in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC) | Adult CIRB - Late Phase Emphasis | Completed |
S0521 | SWOG | A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL); Phase III | Adult CIRB - Late Phase Emphasis | Completed |
S2001 | SWOG | Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations | Adult CIRB - Late Phase Emphasis | Available to Open |
S1406 | SWOG | Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
S1925 | SWOG | Randomized, Phase II Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study | Adult CIRB - Late Phase Emphasis | Available to Open |
S2206 | SWOG | Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
S0347 | SWOG | A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688097) for Patients with HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III | Adult CIRB - Late Phase Emphasis | Completed |